AI-guided treatment for HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether an artificial intelligence model can help doctors choose the best targeted therapy before surgery for HER2-positive breast cancer (a type of breast cancer with a protein called HER2). The goal is to improve how well the treatment works and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18–75 years old
- You have stage II–III HER2-positive breast cancer that hasn't spread to other parts of your body
- Your cancer is confirmed by lab tests showing HER2 positivity (IHC 3+ or IHC 2+ with positive ISH)
- You have not received any prior chemotherapy, targeted therapy, or other cancer treatments
- Your heart function, kidney function, and blood counts are healthy enough for treatment
- You are willing to use effective birth control during the trial and for 3 months after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This study uses artificial intelligence to look at your tumor samples and predict how well pyrotinib (a targeted pill) will work for your advanced breast cancer. It may help guide future treatment decisions by finding patterns that predict response.
This study tests whether giving two drugs (SHR-A1811 and pertuzumab) before surgery can shrink HER2-positive breast cancer tumors. It aims to see if this combination improves treatment outcomes for patients with stage II or III disease.
This study compares a new antibody-drug conjugate (SHR-A1811) with a combination of two oral drugs (pyrotinib and capecitabine) for women with HER2-positive advanced breast cancer that has stopped responding to trastuzumab (Herceptin). It aims to see which treatment works better.
This study tests a new drug (SHR-1811) combined with a standard chemotherapy drug (carboplatin) for advanced breast cancer that shows HER2, even at low levels. It may offer a new option for people whose cancer has stopped responding to previous treatments.
This trial tests a new drug, SHR-A1811, given alone or followed by a standard treatment, before surgery for early-stage HER2-positive breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.